Anabolic therapies

Clinics in Laboratory Medicine

Volumn 20, Issue 3, 2000, Pages 623-637

  Marcus, R ^a  

^a VA PALO ALTO HEALTH CARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANABOLIC AGENT; ANDROGEN; BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; CALCIUM; FLUORIDE; GROWTH HORMONE; PARATHYROID HORMONE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; VITAMIN D;

BONE DENSITY; BONE MINERAL; BONE REMODELING; DRUG EFFICACY; OSTEOPOROSIS; PRIORITY JOURNAL; REVIEW;

EID: 0033842887     PISSN: 02722712     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0272-2712(18)30057-x     Document Type: Review

References (63)

1. Treatment of osteoporosis with calcitonin, with and without growth hormone
2. Effects of growth hormone in osteoporosis
3. Fluoride therapy for osteoporosis
4. High-affinity androgen binding and androgenic regulation of alpha 1(1) procollagen and transforming growth factor-beta steady state messenger ribonucleic acid levels in human osteoblast-like osteosarcoma cells
5. Effects of interleukin-1 on bone turnover in normal mice
6. Effect of excess endogenous androgens on bone density in young women
7. 17β-Estradiol and continuous norethisterone: A unique treatment for established osteoporosis in elderly women
8. Evidence of steroid receptors in human osteoblast-like cells
9. Bone remodeling
10. Interleukin-6 is produced by bone and modulated by parathyroid hormone
11. Prevention of estrogen deficiency-related bone loss with human parathyroid hormone-(1-34). A randomized controlled trial
12. Parathyroid hormone for the prevention of bone loss induced by estrogen deficiency
13. Effect of an intermittent weekly dose of human parathyroid hormone (1-34) on osteoporosis: A randomized double masked prospective study using three dose levels
14. 3 or intermittent calcium infusion therapy on bone mineral content, bone remodeling and fracture rate in symptomatic osteoporosis: A double-blind controlled study
15. Increased trabecular bone mass in rats treated with human synthetic parathyroid hormone
16. Loss of the anabolic effect of parathyroid hormone on bone after discontinuation of hormone in rats
17. Effect of growth hormone on skeletal mass in adult dogs
18. Design considerations for clinical investigations of osteoporosis
19. Effects on bone in vitro of bovine parathyroid hormone and synthetic fragments representing residues 1-34, 2-34, and 3-34
20. Increase of vertebral density by combination therapy with pulsatile 1-38hPTH and sequential addition of calcitonin nasal spray in osteoporotic patients
21. The relationship between changes in femoral bone density and calcium balance in patients with involutional osteoporosis treated with human parathyroid hormone fragment (hPTH 1-34)
22. A comparison of oesterified estrogens with and without methyltestosterone: Effects on endometrial histology and serum lipoproteins in postmenopausal women
23. Human parathyroid hormone (1-34) increases bone mass in ovariectomized and orchidectomized rats
24. A randomized controlled trial to compare the efficacy of cyclical parathyroid hormone versus cyclic parathyroid hormone and sequential calcitonin to improve bone mass in postmenopausal women with osteoporosis
25. Effect of recombinant human growth hormone on metabolic indices, body composition, and bone turnover in healthy elderly women
26. Skeletal effects of cyclic recombinant human growth hormone and salmon calcitonin in osteopenic postmenopausal women
27. IL-6 is produced by osteoblasts and induces bone resorption
28. Increased bone formation by prevention of osteoblast apoptosis with parathyroid hormone
29. Parathyroid hormone and experimental osteosclerosis
30. A randomized trial of sodium fluoride as a treatment for postmenopausal osteoporosis
31. Parathyroid hormone treatment can reverse corticosteroid-induced osteoporosis: Results of a randomized controlled clinical trial
32. Randomized controlled study of effect of parathyroid hormone on vertebral-bone mass and fracture incidence among postmenopausal women on oestrogen with osteoporosis
33. Pre-existing bone loss associated with ovariectomy in rats is reversed by parathyroid hormone
34. Low plasma levels of insulin-like growth factor 1 (IGF-1) in male patients with idiopathic osteoporosis
35. Parathyroid hormone and PTH-like protein stimulate interleukin-6 production by osteogenic cells: A possible role of interleukin-6 in osteoclastogenesis
36. Parathyroid hormone stimulates the proliferation of cells derived from human bone
37. Preservation of bone mass in hypogonadal female monkeys with recombinant human growth hormone administration
38. Normal and abnormal bone remodeling in man
39. Fluoride salts are no better at preventing new vertebral fractures than calcium-vitamin D in postmenopausal osteoporosis. The FAVO study
40. Effects of nandrolone decanoate and anti-resorptive therapy on vertebral density in osteoporotic women
41. Increased bone formation by intermittent parathyroid hormone administration is due to the stimulation of proliferation and differentiation of osteoprogenitor cells in bone marrow
42. The mitogenic effect of parathyroid hormone is associated with E2F-dependent activation of cyclin-dependent kinase 1 in osteoblast precursors
43. Osteoporosis in men: Epidemiology, pathophysiology, and clinical characterization
44. Slow-release sodium fluoride in the management of postmenopausal osteoporosis. A randomized clinical trial
45. Growth hormone replacement in healthy older men improves body composition but not functional ability
46. Bone structure in postmenopausal hyperparathyroid, osteoporotic, and normal women
47. Chronic response of dogs to parathyroid hormone infusion
48. Calcium shift into bone causing transient hypocalcemia after injection of parathyroid hormone
49. Effects of nandrolone decanoate on bone mass in established osteoporosis
50. hPTH 1-34 treatment of osteoporosis with added hormone replacement therapy: Biochemical, kinetic and 1-histological responses
51. Treatment of osteoporosis with human parathyroid peptide and observations on effect of sodium fluoride
52. Anabolic effect of human parathyroid hormone fragment (hPTH 1-34) therapy on trabecular bone in involutional osteoporosis: Report of a multi-centre trial
53. Effect of fluoride treatment on the fracture rate in postmenopausal women with osteoporosis
54. Effects of human growth hormone in men over 60 years old
55. On the stimulation of new bone formation with parathyroid extract and irradiated ergosterol
56. Restoration of spinal bone in osteoporotic men by treatment with human parathyroid hormone (1-34) and 1,25-dihydroxyvitamin D
57. Sex steroids and bone density in premenopausal and postmenopausal women
58. Parathyroid hormone stimulates the bone apposition rate independently of its resorptive action: Differential effects of intermittent and continuous administration
59. Aromatase activity in human osteoblast-like cells
60. The induction of osteopetrotic changes in hypophysectomized thyroparathyroidectomized and intact rats of various ages
61. Comparison of oral estrogen and estrogens plus androgen on bone mineral density, menopausal symptoms and lipid-lipoprotein profiles in surgical menopause
62. Conversion of testosterone to estrogens in castrated, adrenalectomized human females
63. Anabolic effects of parathyroid hormone in ovariectomized rats